BMS launches digital Advocacy Exchange for patient groups affected by COVID-19Bristol Myers-Squibb and digital health firm GRYT Health have teamed up to develop an ‘Advocacy Exchange’ virtual platform Share XBMS launches digital Advocacy Exchange for patient groups affected by COVID-19https://pharmaphorum.com/views-analysis-digital/bms-launches-digital-advocacy-exchange-for-patient-groups-affected-by-covid-19/
ASCO 2020 round-up: Virtual conference still delivers the dramaASCO may have been virtual this year because of the COVID-19 pandemic, but there were still some show-stopping Share XASCO 2020 round-up: Virtual conference still delivers the dramahttps://pharmaphorum.com/views-analysis-oncology/asco-2020-round-up-virtual-conference-still-delivers-the-drama/
The future of real world evidenceIncreasing interest in real-world evidence (RWE) across all stakeholder groups has the industry buzzing about its current role Share XThe future of real world evidencehttps://pharmaphorum.com/r-d/views-analysis-r-d/future-real-world-evidence-rwe/
BMS plans another tack as EU regulators knock back lung cancer comboBristol-Myers Squibb has withdrawn a European filing of its immunotherapy combination of Opdivo and Yervoy in first line Share XBMS plans another tack as EU regulators knock back lung cancer combohttps://pharmaphorum.com/news/bms-withdraws-eu-filing-for-opdivoyervoy-in-nsclc/
2019: the year of the pharma mega-merger2019 will be remembered as the year of the pharma mega-merger. Richard Staines looks back at a year Share X2019: the year of the pharma mega-mergerhttps://pharmaphorum.com/views-and-analysis/2019-the-year-of-the-pharma-mega-merger/
BMS has another Opdivo setback after liver cancer trial failureBristol-Myers Squibb’s cancer immunotherapy Opdivo has suffered another setback after it failed to improve on standard care in Share XBMS has another Opdivo setback after liver cancer trial failurehttps://pharmaphorum.com/news/bms-has-another-opdivo-setback-after-liver-cancer-trial-failure/
BMS reveals its post-Celgene takeover management teamBristol-Myers Squibb has announced its new-look leadership after the Celgene takeover goes through, and it reveals a mixed Share XBMS reveals its post-Celgene takeover management teamhttps://pharmaphorum.com/news/bms-post-celgene-takeover-management-team/
BMS’ Opdivo fails late-stage brain cancer testBristol-Myers Squibb has run into yet another hurdle trying to extend the use of its immuno-oncology blockbuster Opdivo Share XBMS’ Opdivo fails late-stage brain cancer testhttps://pharmaphorum.com/news/bms-opdivo-fails-late-stage-brain-cancer-test/
Digital health round-up: Expert team prepares for digital transformation of NHS and moreEngland’s NHS is gearing up towards the ‘go live’ of a new digital transformation team that aims to Share XDigital health round-up: Expert team prepares for digital transformation of NHS and morehttps://pharmaphorum.com/views-analysis-digital/digital-health-round-up-expert-team-prepares-for-digital-transformation-of-nhs-and-more/
